Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2013 Jan;11(1):69-78. doi: 10.1586/eri.12.149.

Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review.

Author information

1
Alfa Institute of Biomedical Sciences, 9 Neapoleos Street, 151 23 Marousi, Athens, Greece. m.falagas@aibs.gr

Abstract

The authors sought to evaluate the impact of ertapenem use on the resistance of Gram-negative bacteria (in general and in specific species) to group 2 carbapenems. PubMed and Scopus databases were systematically searched. Eight studies were included; all reported on Pseudomonas aeruginosa and four reported on Enterobacteriaceae. Five studies did not show any difference in group 2 carbapenem resistance for P. aeruginosa, while three reported a significant decline after ertapenem introduction. Three studies did not show any difference in group 2 carbapenem resistance between the compared periods for Enterobacteriaceae and one study did not present a statistical analysis. In conclusion, the currently available data suggest that ertapenem use does not affect the resistance of Gram-negative bacteria to group 2 carbapenems.

PMID:
23428103
DOI:
10.1586/eri.12.149
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center